Clinical Trials Browser

Phase 1 × Crizotinib × Thoracic × Clear all

NCT02511184 2019-07-01

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Phase 1 Terminated

9 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01998126 2018-04-02

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00965731 2015-10-28

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

Phase 1 Completed

27 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01121575 2015-10-28

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

Phase 1 Completed

70 enrolled 50 charts

Carcinoma, Non-Small-Cell Lung